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ABSTRACT
Background and the purpose of the study:  In Parkinson›s disease (PD) prolong use of L-DOPA 
causes some motor disorders such as wearing-off and L-DOPA induced dyskinesia (LID). In this 
investigation the effect of 8-OHDAPT, as a 5-HT1A agonist on anti-cataleptic effect of L-DOPA 
in 6-hydroxydopamine (6-OHDA) lesioned male Wistar rats was investigated.
Methods: Catalepsy was induced by unilateral injection of 6-OHDA (8 µg/2µl/rat) into the 
central region of the SNc. After 3 weeks as a recovery period, animals received intraperitoneally 
(i.p.) L-DOPA (15 mg/kg) twice daily for 20 days, and anti-cataleptic effect of L-DOPA was 
assessed by bar-test at days of 5, 10, 15 and 20.
Results and major conclusion: The results showed that L-DOPA had anti-cataleptic effect only 
until the day of 15, and its effect was decreased on the day of 20. On the day of 21, rats 
were co-injected with three different doses of 8-OHDAPT (0.1, 0.5 and 2.5 mg/kg, i.p.) and 
L-DOPA (15 mg/kg, ip). 8-Hydroxy-2-(di-n-propylamino) tetralin (8-OHDAPT) improved 
anti-cataleptic effect of L-DOPA at the dose of 0.5 mg/kg. Moreover the effect of 8-OHDAPT 
on anti-cataleptic effect of L-DOPA (15 mg/kg, ip) was abolished by 1-(2-methyoxyphenyl)-
4-[4-(2-phthalamido) butyl] piperazine hydrobromide (NAN-190; 0.5 mg/kg, i.p.) as a 5-HT1A 
receptor antagonist. According to the obtained results, it may be concluded that activation of 
5-HT1A receptors by 8-OHDAPT may improve anti-cataleptic effect of L-DOPA in a 6-OHDA- 
induced rat model of PD. Further studies are required to clarify the exact mechanism of 
interaction between 5-HT1A and dopaminergic neurons.
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INTRODUCTION
L-Dihydroxyphenylalanine (L-DOPA) is the most 
effective drug which is commonly used in PD (1). 
However prolong use of L-DOPA may cause some 
motor problems such as wearing-off and L-DOPA 
induced dyskinesia (LID) (2). Although the main 
mechanisms underlying these complications are 
unclear but they are attributed to the maladaptive 
plastic changes in the brain such as changes in 
the synthesis, release, inactivation and vigorous 
axonal sprouting of dopamine (3).
There are some evidences that pronounce 
axial role of serotonergic system in the PD. 
Accordingly, in the 6-hydroxy dopamine lesioned 
rats, increase of serotnine levels (3) and hyper-
innervation of serotonergic neurons take place 
within the striatum and these neurons compensate 
some roles of the lost dopaminergic neurons 
(4). In addition to these, serotonergic neurons 
express aromatic L-amino acid decarboxylase and 
vesicular monoamine transporter 2, which convert 
L-DOPA to the dopamine (3). It has been shown 
that L-DOPA derived dopamine is co-stored with 
serotonin into same vesicles and acts as a false 
transmitter (5). 
Dopaminergic neurons are able to keep dopamine 
levels at the physiologic levels (6). This regulatory 
mechanism is mediated by D2 auto-receptors and 
dopamine transporters (7). However, serotonergic 
neurons have not these regulatory components 
and they are not able to exert enough control 
on the release of dopamine to the striatum (2). 
Therefore release of dopamine from these neurons 
has an activity-dependent-fashion (6). Under this 
condition fluctuation in dopamine levels result in 
intermittent activation of dopamine receptors and 
motor fluctuation (2). It has been shown that 5-HT1A 
receptors are present on dorsal raphe neurons with 
efferents to the striatum  and on cortical neurons 
that send glutamatergic projections to the basal 
338ganglia (8). Stimulation of 5-HT1A receptors in these 
regions leads to dopamine release (9) via inhibition 
of adenyl cyclase and opening of potassium 
channels (10). Recently it was shown that 5-HT1A 
  agonists exert anti-cataleptic effect in animal   
model of PD (11, 12) and also regulatory effect of 
5-HT1A receptors on L-DOPA derived dopamine 
levels has been reported (13). However there is no 
report about 5-HT1A effects on anti-cataleptic effect 
of L-DOPA. In this study effect of 8-hydroxy-2-
(di-n-propylamino) tetralin (8-OH-DAPT), as a 
5-HT1A receptor agonist on anti-cataleptic effect of 
L-DOPA in 6-hydroxydopamine-lesioned rats was 
investigated.
MATERIAL AND METHODS
Chemicals
All chemicals except L-DOPA and Carbidopa 
which were obtained from Ramopharmin, Iran 
were purchased from Sigma Chemical Co. (USA). 
L-DOPA solutions were made freshly on the days 
of experimentation by dissolving in 0.9% NaCl. The 
drugs other than 6-hydroxydopamine (6-OHDA) 
which was injected into left subestentia nigra were 
injected intraperitoneally (i.p.). Movement disorder 
was assessed by bar test on 5, 60, 120 and 180 min 
after drugs administration
Animals
Seventy two male wistar rats weighting 180-200g 
were housed in standard polypropylene cages, 
four per cage, under 12:12 light/dark schedule and 
at 25±2°C with free access to food and water. All 
experiments were performed according to the ethical 
guideline of Tabriz University of Medical Sciences 
for the care and use of laboratory animals. 
6-OHDA-induced lesion of SNc
Rats were anaesthetized deepply by intraperitoneal 
(i.p.) injection of Ketamine (50 mg/kg) and 
xylazine (5 mg/kg). Then their heads were fixed 
in  a  stereotactic  apparatus  frame  at  flat  skull 
position. The scalp was shaved and scraped with 
iodine and a small central incision made to appear 
skull. A 23 gauge sterile stainless steel cannula 
as a guide cannula, was firmly implanted to the 
injection site for subsequent insertion of the 
injection tube into the SNc. The coordinates for 
this position were determined according to the 
rat brain in stereotaxic coordinates (14): which 
are anteroposterior from bregma (AP)=-5 mm, 
mediolateral from the midline (ML)=-2.2 mm and 
dorsoventral from the skull (DV)=-8.8 mm. The 
guide cannula was then secured to the cranium 
with dental cement. Desipramine (25 mg/kg) was 
injected intraperitoneally 30 min before intranigral 
injection of 6-OHDA to avoid destruction of 
noradrenergic neurons (15). Then 6-OHDA (8 μg/ per 
rat in 2 μl of saline containing  0.2 % w/v of ascorbic 
acid) was infused by infusion pump at the flow rate 
of 0.2 μl/min into the left subestentia nigra. At the 
end of injection, the tube was kept for an additional 2 
min and then slowly withdrawed. All these procedure 
were exploited for control animals except that they 
were injected 2 μl vehicle of 6-OHDA (0.9% saline 
containing 0.2% (w/v) ascorbic acid). After three 
weeks as a recovery period, only rats that showed 
marked catalepsy in bar test were subjected to further 
experimentation. Then parkisonian rats were divided 
randomly into groups of 8 and treated with L-DOPA 
(15 mg/kg, i.p.) twice daily (9 AM and 9 PM) for 
20 days. Peripheral metabolism of L-DOPA was 
inhibited by concomitant administration of carbidopa 
(1.5 mg/kg, i.p.). Other drugs such as 8-OH-DPAT 
and NAN-190 were injected once on the day of 21. 
Catalepsy test
Catalepsy was measured by means of a standard 
bar test. In this method, forepaws of rats were 
placed over a 9 cm high standard wooden bar 
and duration of retention of rats in this imposed 
posture was considered as a bar test elapsed time 
(16). The end point of catalepsy was considered 
to occur when both front paws were removed 
from the bar or if the animal moved its head in an 
exploratory manner. A cut-off time of 720 seconds 
was applied. All observations were carried out by a 
person who was unaware from entity of treatment.
Statistical analyses
Statistical analysis of each data set was calculated 
by use of SigmaStat software.  Data were 
expressed as the mean+SEM, and analyzed by 
one-way ANOVA in each experiment. In the case 
of significant variation (p<0.05), the values were 
compared by Tukey test. 
RESULTS
Effect of intra-SNc injected 6-OHDA on bar test
Catalepsy elapsed time was measured in three 
groups of rats that were as normal, control and 
6-OHDA (8 mg/2 μl/rat)-lesioned groups. As it has 
been  shown  in  figure  1,  6-OHDA  (8  mg/2μl/rat) 
compared with  normal and control group was able 
to induce (p<0.001) marked catalepsy. 
Effect of chronic administration of L-DOPA on bar 
test
The impact of L-DOPA (15 mg/kg, i.p.) and its 
vehicle on 6-OHDA-induced catalepsy was assessed 
for 20 days. In these groups catalepsy was tested 
on days of 5, 10, 15 and 20. There was significant 
reduction (p<0.0001) on bar test elapsed time in 
L-DOPA treated rats on days of 5, 10, 15, whereas 
it›s anti-cataleptic effect was abolished on the day of 
20 (Fig. 2A). No alteration was observed on bar test 
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Figure 2. The results of bar test in 6-OHDA (8 μg/2 μl/rat) lesioned rats injected with L-DOPA (15 mg/kg) (Fig. 2A) and L-DOPA›s 
vehicle (Fig. 2B) twice daily on the days of 5, 10, 15 and 20. Each bar represents the mean±SEM of elapsed time (s), n=8 rats for each 
group; *** p<0.001 when compared with 6-OHDA lesioned rats. (L=L-DOPA on days of 5, 10, 15, 20) ; (V=Vehicle on days of 5, 10, 
15, 20)
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Figure 1. The results of bar test in normal, control and 6-OHDA (8 μg/2μl/rat) lesioned rats. Each bar shows the mean±SEM of elapsed 
time (s), n=8 rats for each group; *** p<0.001 when compared with normal and  control groups.
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effective adjuvant therapy for the treatment of motor 
fluctuations  during  long  term  L-DOPA  therapy  in 
PD.  Further investigations are required to determine 
exact mechanisms underlying interaction between 
serotonergic and dopaminergic systems.
Figure 4. The bar test results of co-treatment of NAN-190(0.5 mg/kg) with L-DOPA (15 mg/kg) and 8-OH-DAPT (0.5 mg/kg) on the day 
of 21, in 6-OHDA lesioned rats and in 6-OHDA lesioned rats treated with L-DOPA (15 mg/kg) on the day of 21  and 6-OHDA(8 μg/2μl/
rat) lesioned rats. Each bar shows the mean±SEM of elapsed time (s), n=8 rats for each group; *p<0.05 and ** p<0.01 when compared 
with 6-OHDA lesioned rats, #p<0.05 and ##p<0.01 when compared with 6-OHDA lesioned rats that co-treated with L-DOPA (15 mg/kg) 
and 8-OH-DAPT (0.5 mg/kg) on the day of 20.
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